New prognostic factors for breast cancer recurrence

Seminars in Oncology

Volumn 28, Issue 1, 2001, Pages 53-67

  Isaacs, Claudine ^a,b   Stearns, Vered ^a   Hayes, Daniel F ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CATHEPSIN D; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; DEATH; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0035110932     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90045-4     Document Type: Article

References (88)

1. Effects of adjuvant tamoxifen of cytotoxic therapy on mortality in early breast cancer
2. Meeting highlights: International consensus panel on the treatment of primary breast cancer
3. Prognostic factors and treatment decisions in axillary-node-negative breast cancer
4. Prognostic variables in node-negative and node-positive breast cancer
5. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
6. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
7. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
8. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
9. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons
10. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up
11. Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up
12. Status of breast cancer prognostication based on histopathologic data
13. Histological grading and prognosis in breast cancer
14. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
15. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas
16. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06
17. The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy
18. Interobserver reproducibility of histopathological features in stage II breast cancer
19. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer
20. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years
21. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast
22. Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
23. How to use prognostic factors in axillary node-negative breast cancer patients
24. Time-dependence of hazard ratios for prognostic factors in primary breast cancer
25. S-phase fraction and breast cancer - A decade of experience
26. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer
27. DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study
28. CMF vs. CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT0102
29. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer
30. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer
31. Prognostic and predictive value of thymidine labelling index in breast cancer
32. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel
33. Detection and significance of occult axillary metastatic disease in breast cancer patients
34. Importance of tumor cells in axillary node sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma
35. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma
36. Occult axillary lymph-node micrometastases in breast cancer
37. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
38. Meta-analyses of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated
39. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
40. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
41. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
42. Clinical significance of HER-2/neu overexpression: Part I
43. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer
44. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
45. Prognostic importance of c-erbB-2 expression in breast cancer
46. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer
47. c-erbB2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
48. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study
49. c-erbB2 as a prognostic factor in breast cancer: A meta-analysis
50. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
51. What is the evidence that tumors are angiogenesis dependent?
52. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
53. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
54. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer
55. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
56. Angiogenesis in breast cancer: A comparative study of the observer variability of methods for determining microvessel density
57. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
58. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
59. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma
60. Cathepsin D and breast cancer
61. A secreted glycoprotein induced by estrogen in human breast cancer cell lines
62. Cathepsin D: An independent prognostic factor for metastasis of breast cancer
63. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer
64. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: A meta-analysis
65. Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients
66. Cathepsin D expression by cancer and stromal cells in breast cancer: An immunohistochemical study of 1348 cases
67. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients
68. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
69. Urokinaseplasminogen activator, a new and independent prognostic marker in breast cancer
70. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
71. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
72. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
73. Plasminogen activator inhibitor type 2 in breast cancer
74. Dissemination risk index based on plasminogen activator system components in primary breast cancer
75. Interim analysis of a randomized trial on risk-adapted adjuvant chemotherapy in node-negative breast cancer patients guided by the prognostic factors uPA and PAI-1
76. Dysregulation of apoptosis in cancer
77. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results
78. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis
79. Prognostic and predictive value of p53 and p21 in breast cancer
80. Bcl-2 protein expression and long-term survival in breast cancer
81. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
82. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases
83. Primary chemotherapy of resectable breast cancer
84. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
85. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
86. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
87. Long-term follow up of stage III breast cancer-combined modality treatment with anthracycline containing chemotherapy (CT): The MD Anderson experience